Published in Gene Therapy Weekly, December 19th, 2002
Mengfen Li and colleagues, University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, reported using such a combination to combat HNSCC in both nude and immunocompetent mice.
According to Li and coauthors, the combination therapy included endostatin, a natural angiogenesis inhibitor, and epidermal growth factor receptor antisense gene therapy administered in liposomes. The researchers segregated mice into four groups and delegated them to receive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.